Navidea enrolls 1st patient in Phase III trial of NAV4694

06/27/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals said it has signed up the first patient in a Phase III trial that will test the PET imaging agent NAV4694. The study will evaluate the safety and efficacy of the agent in identifying beta amyloid in end-of-life patients with and without dementia. The study, to eventually include 275 individuals, will compare imaging data during life with autopsy findings.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA